Active surveillance for the management of localized prostate cancer (Cancer Care Ontario guideline): American society of clinical oncology clinical practice guideline endorsement Academic Article uri icon

Overview

MeSH Major

  • Practice Guidelines as Topic
  • Prostatic Neoplasms

abstract

  • For most patients with low-risk (Gleason score ≤ 6) localized prostate cancer, active surveillance is the recommended disease management strategy. Factors including younger age, prostate cancer volume, patient preference, and ethnicity should be taken into account when making management decisions. Select patients with low-volume, intermediate-risk (Gleason 3 + 4 = 7) prostate cancer may be offered active surveillance. Active surveillance protocols should include prostate-specific antigen testing, digital rectal examinations, and serial prostate biopsies. Ancillary radiologic and genomic tests are investigational but may have a role in patients with discordant clinical and/or pathologic findings. Patients who are reclassified to a higher-risk category (Gleason score ≥ 7) or who have significant increases in tumor volume on subsequent biopsies should be offered active therapy.

publication date

  • June 20, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2015.65.7759

PubMed ID

  • 26884580

Additional Document Info

start page

  • 2182

end page

  • 90

volume

  • 34

number

  • 18